Following our finding that BCL2L10 is implicated in melanoma resistance to cisplatin and ABT-737, we wanted to evaluate whether the effect of BCL2L10 expression in response to these drugs was also observed in the context of simultaneous inhibition of BRAF by the BRAFV600E inhibitor PLX-4032. The gene discussed is BCL2L10; the disease is melanoma.